EP
RARE icon

Eversept Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Eversept Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Sell
62,575
-254,607
-80% -$5.73M 0.07% 100
2025
Q4 		$7.3M Buy
+317,182
New +$10.4M 0.37% 65

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Eversept Partners's RARE Position: Q1 2026 in Review

Eversept Partners reduced its Ultragenyx Pharmaceutical (RARE) stake by 80% in Q1 2026, selling an estimated $5.73M and leaving 62,575 shares worth $1.31M. The position accounts for 0.07% of the portfolio, ranked #100.

Eversept Partners first reported a position in RARE in Q4 2025 and has held it in 2 quarters since. The position peaked at $7.3M in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Eversept Partners held 62,575 shares of Ultragenyx Pharmaceutical worth $1.31M as of Q1 2026.
  • Eversept Partners sold 254,607 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $5.73M.
  • Ultragenyx Pharmaceutical made up 0.07% of Eversept Partners's portfolio in Q1 2026, its #100 holding.
  • Eversept Partners first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • Eversept Partners's Ultragenyx Pharmaceutical position peaked at $7.3M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.